- Keywords
- BACTROBAN,
- MeSH
- Dermatitis, Atopic drug therapy MeSH
- Humans MeSH
- Ointments therapeutic use MeSH
- Check Tag
- Humans MeSH
- MeSH
- Anti-Bacterial Agents MeSH
- Administration, Topical MeSH
- Bacterial Infections drug therapy MeSH
- Child MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Burns drug therapy MeSH
- Child, Preschool MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Child, Preschool MeSH
64 stran : tabulky, grafy ; 18 cm
Brožura se zaměřuje na Bactroban, přípravek obsahující antibiotikum mupirocin, který se používá v terapii kožních infekcí. Určeno odborné veřejnosti.
- MeSH
- Anti-Bacterial Agents therapeutic use MeSH
- Skin Diseases, Infectious drug therapy MeSH
- Ointments therapeutic use MeSH
- Mupirocin therapeutic use MeSH
- Conspectus
- Farmacie. Farmakologie
- NML Fields
- farmacie a farmakologie
- dermatovenerologie
- NML Publication type
- brožury
- informační publikace
- MeSH
- Anti-Bacterial Agents MeSH
- Administration, Topical MeSH
- Bacterial Infections drug therapy MeSH
- Child MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Burns drug therapy MeSH
- Child, Preschool MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Child, Preschool MeSH
Cíl: Ukázat spektrum nemocí, které vyvolávají meticilin-rezistentní kmeny Staphylococcus aureus (MRSA). Posoudit účinnost postupů, které mohou vést k vyléčení infekce MRSA, případně k eradikaci kolonizace. Metody. Klinická studie sledující průběh infekce či kolonizace MRSA u pacientů hospitalizovaných na infekční klinice FN Na Bulovce v době 1.1. 2004-31. 8. 2005. Do studie jsou zahrnuty i výsledky ambulantního sledování těchto pacientů. Výsledky. Do studie bylo zařazeno 59 pacientů; v 22 případech se jednalo o infekci a v 37 případech o kolonizaci MRSA. U 14 pacientů byla zjištěna kolonizace v několika anatomických lokalitách současně, u 15 pacientů byla kromě infekce MRSA zjištěna ještě kolonizace v jiné lokalizaci. Z infekcí byly nejčastější infekce měkkých tkání (Ux), nejčastějším místem kolonizace byla nosní sliznice (14x) a kožní defekty (8x). V léčbě lehkých infekcí se dobře osvědčil kotrimoxazol, v léčbě nazální kolonizace mupirocin ve formě masti (Bactroban ung). Při šestiměsíčním ambulantním sledování 25 MRSA-pozitivních pacientů jsme zjistili vymizení kmene MRSA u 7 osob (28 %). Závěr. U významné části MRSA-pozitivních pacientů dochází po léčbě nebo i spontánně k vymizení kmene MRSA. Vývoj kolonizace MRSA je možné sledovat pomocí ambulantní dispenzarizace.
Purpose: To present the range of diseases produced by a methicilhn-resistant strain of Staphylococcus aureus (MRSA). To assess the efficacy of procedures likely to cure MRSA infections and possibly to eradicate colonization. Methods: Clinical trial studying the course of MRSA infections or colonization of in-patients, treated at the Department of Infectious Diseases of the Teaching Hospital Na Bulovce e, Prague, between 1 January 2004 and 31 August 2005. The trial also took into account the results of these patients' follow-up as out-patients. Results: Included in the trial were 59 patients - 22 presenting MRSA infections and 37 MRSA colonization. In 14 patients we found simultaneous colonization in several anatomical sites, while in 15 patients we saw, in addition to the MRSA infection, colonization at another site. .Among the infections most frequent were infections of soft tissues (11), while colonization occured chiefly in the nasal mucosa (14) and in skin defects (8). In the treatment of mild infections we had good results with co-trimoxazole, in the treatment of coIonizations mupirocine in the form of ointment (Bactroban ung.). During a six-month follow-up of 25 MRSA-positive patients at our Out-patient Dpt. we saw the disappearance of the MRSA strain in 7 subjects (28 %). Conclusion: In a significant proportion of MRSA-positive patients the MRSA strain disappears either after treatment or spontaneously. The development of MRSA colonization may be studied in out-patient follow-ups.
- MeSH
- Anti-Bacterial Agents MeSH
- Chloramphenicol therapeutic use MeSH
- Trimethoprim, Sulfamethoxazole Drug Combination therapeutic use MeSH
- Humans MeSH
- Mupirocin therapeutic use MeSH
- Prospective Studies MeSH
- Methicillin Resistance MeSH
- Staphylococcus aureus pathogenicity drug effects MeSH
- Vancomycin therapeutic use MeSH
- Check Tag
- Humans MeSH
- Keywords
- Retapamulin, Framykoin, Bactroban, Fucidin,
- MeSH
- Anti-Bacterial Agents * administration & dosage classification therapeutic use MeSH
- Drug Resistance, Microbial MeSH
- Anti-Infective Agents, Local * MeSH
- Cellulitis physiopathology therapy MeSH
- Erysipelas physiopathology therapy MeSH
- Folliculitis physiopathology MeSH
- Furunculosis physiopathology therapy MeSH
- Impetigo MeSH
- Skin Diseases, Infectious * classification physiopathology therapy MeSH
- Clinical Trials, Phase III as Topic MeSH
- Humans MeSH
- Mupirocin pharmacology MeSH
- Randomized Controlled Trials as Topic MeSH
- Staphylococcal Skin Infections physiopathology MeSH
- Streptococcal Infections physiopathology MeSH
- Hair Follicle physiopathology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Review MeSH
UNLABELLED: The need for suitable selective cultivation media for the isolation of Bifidobacterium spp. continues to be a real concern in the field of intestinal microbiology. Isolation of bifidobacteria from human and animal faecal samples using selective agar plating may be problematic especially in samples with increased clostridial counts than bifidobacterial counts. Due to the absence of anticlostridial agents in existing selective media, clostridia can displace bifidobacteria resulting in incorrect estimation of their counts. Therefore, we supplemented the existing selective medium 'modified Wilkins Chalgren agar with mupirocin' (MWM) with 90 mg l(-1) of 8-hydroxyquinoline (8HQ), which was recently proved to act selectively against clostridia. The newly composed 'modified Wilkins-Chalgren agar with 8HQ' (MWMQ) was tested on pure bifidobacterial and clostridial strains, their mixtures, and using faecal samples of mammalian origin; its selectivity was evaluated by genus-specific identification of isolates. The results demonstrated that the presence of 8HQ in this agar eliminated the growth of nonbifidobacterial strains on MWMQ compared to that on MWM, whereas the recovery of bifidobacterial counts was at satisfactory levels. In conclusion, MWMQ could be recommended for bifidobacterial isolation from human and animal faeces especially when bifidobacteria are not numerically dominant and there are chances of clostridial contamination. SIGNIFICANCE AND IMPACT OF THE STUDY: Routine isolation of bifidobacteria from mammalian faeces does not use a reliable selective agar with an anticlostridial agent. Overgrowth of clostridia may result in incorrect estimation of bifidobacterial counts. Thus, in order to improve the selectivity of existing media for bifidobacterial isolation, we chose the modified Wilkins-Chalgren agar with mupirocin and supplemented it with 8-hydroxyquinoline (8HQ), a molecule that shows anticlostridial activity without affecting the growth of bifidobacteria. This newly composed medium showed enhanced selectivity and specificity compared to the original medium and therefore, can be recommended for the isolation of bifidobacteria from mammal faeces.
- MeSH
- Agar pharmacology MeSH
- Bacterial Load drug effects MeSH
- Bifidobacterium growth & development isolation & purification MeSH
- Clostridium drug effects growth & development MeSH
- Feces microbiology MeSH
- Culture Media pharmacology MeSH
- Humans MeSH
- Mupirocin pharmacology MeSH
- Oxyquinoline pharmacology MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
